Login to Your Account



Pharmacovigilance enters the FTC biosimilar debate

By Mari Serebrov
Washington Editor

Tuesday, February 4, 2014
Seeing the biosimilar debate as a way to improve pharmacovigilance for all biologics, several biosimilar makers are now pushing for state notification regulations that would lead to transparent and more accurate patient health records.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription